TY - JOUR
T1 - Antibodies to early epsteln-barr virus- induced antigens in burkitt’s lymphoma
AU - Henle, Gertrude
AU - Henle, Werner
AU - Klein, George
AU - Gunven, Peter
AU - Clifford, Peter
AU - Morrow, Richard H.
AU - Ziegler, John L.
N1 - Funding Information:
3 Recipient of Public Health Service Career Award 5-K6-Al-22,683 from the National Institutes of Health. 4 The Virus Laboratories at The Children's Hospital of Philadelphia and the School of Medicine, University of Pennsylvania, Philadelphia, Penna; 5 Department of Tumor Biology, Karolinska Institute Medical School, Stockholm, Sweden; G Kenyatta National Hospital, Nairobi, Kenya. 7 Lymphoma Treatment Center, Mulago Hospital, Kampala, Uganda;
Funding Information:
2 This investigation was supported by Public Health Service grant CA 04568 from the National Cancer Institute, contracts PH-43-66-477, PH-43-69-2005, PH-43-67-47, and PH-43-67-1343 within the Special Virus Leukelnia Program, National Cancer Institute, and funds from the Swedish Cancer Society and the British Imperial Cancer Campaign.
PY - 1971/4
Y1 - 1971/4
N2 - The relation between antibodies to early Epstein-Barr virus (EBV)-induced antigens (EA) and antibodies to other EBV-related antigens was investigated as well as the significance of anti-EA in Burkitt’s lymphoma (BL). Anti-EA was clearly distinct from antibodies to EB viral capsid antigens (VCA), EBV-dependent cell membrane antigens, and precipitating antibodies. Whereas anti-EA was found only in sera which showed also anti-VCA at titers of ^1:40, sera with high anti-VCA titers did not necessarily contain anti-EA. This type of discordance was frequent among the relatively few sera from African control children with high anti- VCA titers, but was relatively rare among the many sera with high anti-VCA titers from BL patients. Presence or absence of anti-EA reflects to a considerable extent the prognosis of patients with BL after chemotherapy. Most sera obtained shortly before death had high titers of anti-EA. Among patients who died without anti-EA were several who were moribund when admitted and several in whom death was due to complications while the presenting tumors were in remission. In contrast, over half the patients who survived for at least 2 years, some as long as 9 years to date, lacked this antibody or had only low titers. Recurrences, as late as 5 years after initial successful treatment, were more frequent among long-term survivors who had continuously high anti-EA titers than among patients who were admitted without anti-EA. Possible explanations for the apparent prognostic significance of anti-EA in BL were discussed.—J Nat Cancer Inst 46: 861-871, 1971.
AB - The relation between antibodies to early Epstein-Barr virus (EBV)-induced antigens (EA) and antibodies to other EBV-related antigens was investigated as well as the significance of anti-EA in Burkitt’s lymphoma (BL). Anti-EA was clearly distinct from antibodies to EB viral capsid antigens (VCA), EBV-dependent cell membrane antigens, and precipitating antibodies. Whereas anti-EA was found only in sera which showed also anti-VCA at titers of ^1:40, sera with high anti-VCA titers did not necessarily contain anti-EA. This type of discordance was frequent among the relatively few sera from African control children with high anti- VCA titers, but was relatively rare among the many sera with high anti-VCA titers from BL patients. Presence or absence of anti-EA reflects to a considerable extent the prognosis of patients with BL after chemotherapy. Most sera obtained shortly before death had high titers of anti-EA. Among patients who died without anti-EA were several who were moribund when admitted and several in whom death was due to complications while the presenting tumors were in remission. In contrast, over half the patients who survived for at least 2 years, some as long as 9 years to date, lacked this antibody or had only low titers. Recurrences, as late as 5 years after initial successful treatment, were more frequent among long-term survivors who had continuously high anti-EA titers than among patients who were admitted without anti-EA. Possible explanations for the apparent prognostic significance of anti-EA in BL were discussed.—J Nat Cancer Inst 46: 861-871, 1971.
UR - http://www.scopus.com/inward/record.url?scp=0015040633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015040633&partnerID=8YFLogxK
U2 - 10.1093/jnci/46.4.861
DO - 10.1093/jnci/46.4.861
M3 - Article
C2 - 4324816
AN - SCOPUS:0015040633
SN - 0027-8874
VL - 46
SP - 861
EP - 871
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 4
ER -